Why is that resell?. I am a much larger investor here for a much longer period of time than you or most everyone else here except maybe smalls. I know that cause I organized many shareholders a while back. So believe me, all that i want is for this stock to go up. My main problem with management is that they dont seem to care about share price. When that changes and management walks that walk, instead of their worthless talk, i will be very happy.
Management has criticized me because i have said to them that share price is the only metric that counts for a public company. So, again reseller, you are very wrong, but consistent.
Management must be careful(non transparent) because they do not want to call attention to thier lies, overcompensation, and incompetence.
Ma's old lies extend to hype about India's to saying in an SEC doc they will be profitable in 2014. Their incompetence is very obvious; failing on eecp, paying a flunky to get better insurance coverage, the Dempsy fiasco, the lawsuits, the non accretive acquisitions(could also be put in the lie area), and incestous nature for employees in acquisitions.................could go on.........stock price.
Overcompensation; who thinks Ma should have a package valued at 600,000?
No shorts today at all. This follows my assumption that the runnup on little news inspired some not so deep pocket day traders(tweeter) to get involved in a stock they know or care nothing about. They are just trying to cash out and move on. They sell stupidly. Supply should be done soon but does provide any investors who know the real story here to take advantage of this weakness. Of course, you need a pair which is something most here dont seem to have(SNO). Or you could be just like dimwitted hollis and wait for 10 cents.
Fink should try to get this stock on an elevated OTC exchange. The trading here on little volume is criminal.
Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares down 21 percent in premarket trading on Friday.
The study tested the drug, OHR-102, in combination with Roche Holding AG's Lucentis, in patients with the wet form of age-related macular degeneration, the leading cause of blindness in the elderly
Short, message board legal "experts" working overtime today. At a buck a post, they are soon to be part of the 1% er's. Who needs a real patent attorney when we have these Rhodes Scholars.
Shorts are really desperate if they have to employ these More Ons...................................
This action has nothing to do with a reversal in the general bio market. Look at the april calls. They are now paying 25 cents for the april 5's. Action in sgyp specific and suggest early buyout here. Follow the money
These comments are from an older report which is being updated. Zacks, at no point, questions rgrx's IP protection despite what our knucklehead, message board, crack legal team of Donk and Hollis whine about endlessly. Buy the dips
RegeneRx holds approximately 150 issued patents and filed patent applications worldwide within 14 patent families.
These patients cover peptide compositions, uses and formulations related to dermal and ophthalmic indications and
other organ and tissue repair and regenerative medicine activities, as well as for cosmetic and consumer
applications with Thymosin beta-4 and its related fragments. These include T 4 patents licensed from the NIH
issued in the U.S., Europe, and Asia. These patents begin to expire in July 2019. The company has also licensed all
rights to T 4 applications in respiratory distress syndrome and septic shock from The George Washington
University (GWU), for which, if commercialized, RegeneRx will pay GWU a 4% royalty on sales in these areas.
RegeneRx has filed numerous additional U.S. and international patent applications covering various compositions,
uses, formulations and other components of T 4.
Restasis is a used to increase the eyes ability to produce tears, which may be deficient in patients with ocular
inflammation. It effectively masks the symptoms of dry eyes, but does not go after the underlying cause of the
disease. It s a step-up from OTC dry eye products like Refresh, but does not heal corneal surface defects such as
ulcerations or neurotrophic keratitis (NK). Despite its limitations, for 2011, Allergan sees Restasis sales between
$680 and $710 million. We think there is a significant unmet medical need for a product like RGN-259, a potential
disease modifier, to treat dry eye patients where Restasis fails. At the very least, the RGN-259 my find use in
combination with Restasis to improve tear production and corneal healing
I dont think you will see much short. I think one of the tweeterhead traders who bought the runnup was getting out. Overall, a good day as stock came back nicely and bidders edge higher towards the close.
Might see a Zacks update very soon.
Crazy option trading here on a crushing day in the market. Near the close, a buyer of 2500 of the may double nickel calls at 25 cents, when the bid was 5 cents. That option went to 40 cents as stock headed lower. Many April and Julys also bought. Big premuim expansion......................why?
Maybe big player taking a postion in equity and front running in the option market.
Shorts has tried to say trial wont work or will be delayed. But todays Agreement anouncement confirms results in late April. Call volume supports trial success. May is the place to be
About 900 of the may 40 calls done today. One large buyer on the offer of 376 contracts at 8.6. Some puts sold to pay for them, but stock has to run quite a bit to get those ITM.